Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by Brenda Bartman on Aug 13th, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $42.00.

LYEL has been the topic of a number of analyst reports. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a report on Monday, June 15th. B. Riley Financial started coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price for the company. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Finally, Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th.

Check Out Our Latest Research Report on Lyell Immunopharma

Lyell Immunopharma Stock Down 4.8%

Shares of NASDAQ LYEL opened at $14.17 on Thursday. The stock’s fifty day simple moving average is $13.42 and its 200 day simple moving average is $18.76. The stock has a market capitalization of $347.17 million, a price-to-earnings ratio of -1.10 and a beta of -0.04. Lyell Immunopharma has a 52-week low of $9.28 and a 52-week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 87.60% and a negative net margin of 920,285.25%.The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, analysts anticipate that Lyell Immunopharma will post -7.48 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares during the period. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma in the second quarter worth $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma in the second quarter worth $159,000. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma in the fourth quarter worth $210,000. Finally, Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma during the second quarter valued at $258,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.